Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 ...
Following is a summary of current health news briefs. Novo blames US health system after criticism over Wegovy price, ...